ORKA Chief Medical Officer Joana Goncalves Buys $51K of Stock

Joana Goncalves, the Chief Medical Officer of Oruka Therapeutics, Inc. (ORKA), bought 7,000 shares of the company on June 15, 2026. The transaction was valued at $51,240 and occurred at a price of $7.32 per share. This purchase was disclosed in a regulatory filing with the SEC and represents a move by a top executive to increase her stake in the Menlo Park-based biotechnology firm.

Insider Buying and Selling at Oruka Therapeutics, Inc.

This buy by Goncalves followed other notable insider moves in the same week. On June 12, 2026, Arjun Agarwal, the Senior Vice President of Finance, purchased 9,459 shares at $15.87 per share. Later, on June 15, several executives sold small portions of their holdings. CEO Lawrence Otto Klein sold ,1729 shares at $69.69, while General Counsel Paul Quinlan sold 733 shares at the same price. More recently, on October 15, 2026, Goncalves sold 7,000 shares at $74.81 through a scheduled trading plan, which was a separate event from her June purchase.

Oruka Therapeutics Stock Performance

On Monday, shares of Oruka Therapeutics were trading at $68.86. The stock has experienced a wide range over the last year, hitting a low of $14.89 and a peak of $115.52. While the current price is a retreat from those highs, it stays above the 200-day moving average of $61.44. The company currently has no meaningful P/E ratio because it is not yet profitable, a common situation for clinical-stage biotechs focused on research and development.

Analysts Set New Price Targets

Wall Street professionals have remained quite positive on the company. On September 24, 2026, Wedbush reiterated an Outperform rating with a $165.00 price target, and HC Wainwright & Co. maintained a Buy rating with a $120.00 target. Earlier, on August 11, 2026, Guggenheim reiterated its Buy rating with a $200.00 price target, the highest among recent reports. Currently, 12 analysts cover the stock, and their average price target of $155.00 sits far above the current trading price.

Focus on Immunology and Psoriasis

Oruka Therapeutics is a clinical-stage company working on monoclonal antibody treatments. Their main focus is on inflammatory and immunology issues, specifically psoriasis. Their lead candidate, ORKA-001, is in Phase 2a trials, while ORKA-002 is in Phase 2 trials for psoriatic arthritis and other conditions. Because the company is still testing its primary drugs, investor attention is usually fixed on trial data and clinical milestones.

Future Outlook

Investors are looking toward November 11, 2026, which is the company's next scheduled earnings date. These reports often provide updates on the progress of clinical trials and the company's cash runway. While the June purchase by the Chief Medical Officer showed a commitment to the company's trajectory, the subsequent sales by other executives and her own later planned sale illustrate the frequent balancing of equity holdings at the executive level. Further filings will be necessary to see if management continues to adjust their positions as the Phase 2 trials progress.